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Abstract. This study determined whether the immunoassay for cerebrospinal fluid 14-3-3 protein concentration was sensitive and specific in the diagnosis of naturally occurring clinical scrapie in sheep. Cerebrospinal fluid was collected from 9 sheep with the confirmed diagnosis of scrapie. Additionally, cerebrospinal fluid was collected from 13 clinically normal sheep, which originated from a closely monitored flock with no history of scrapie. Sensitivity and specificity were calculated using standard epidemiological methods. Cerebrospinal fluid immunoassay results did not differ significantly between positive and negative sheep. Test sensitivity varied from 0.55 to 0.66, depending on the choice of test endpoint. Test specificity varied from 0.30 to 0.77, depending on the choice of test endpoint. The 14-3-3 cerebrospinal fluid immunoassay appears to have no value in the diagnosis of clinical scrapie in sheep.
Transmissible spongiform encephalopathies (TSE) have been recognized in several species. [1] [2] [3] [4] 10 These include mink, cattle, human beings, cats, sheep, goats, and nondomesticated Cervidae. Proposed etiologic agents include a very small virus and a abnormally folded protein acting as a template that induces identical abnormal folding of normal prion protein molecules. [1] [2] [3] 10 Clinical signs common to TSE syndromes include chronic weight loss and neurological deficits. 2, 3, 10, 16 These syndromes are invariably fatal, and no effective treatment has been identified.
The diagnosis of TSE is problematic. Traditionally, the presumptive diagnosis of TSE has been based on the postmortem histopathologic examination of nervous tissue. Either immunohistochemical staining of tissues prior to histologic examination or Western blot assays on neuronal tissue increase the sensitivity and accuracy of TSE diagnosis. 11, 12 The scrapie agent elicits no detectable immune response, rendering traditional immunodiagnostic approaches ineffective. Bioassay systems in which laboratory animals are inoculated with nervous tissue are complicated by variable sensitivity, the inherent risks to the patient associated with brain biopsies, and the incubation time between inoculation of the test animal and the recognition of clinical signs.
Novel diagnostic strategies are currently being developed that may permit accurate, early recognition of TSE. 13 The most promising of these strategies is the immunohistochemical (IHC) recognition of misfolded prion protein (PrP Sc ) in tissue biopsies. Another such diagnostic test is an immunoassay detecting altered protein composition in cerebrospinal fluid. Previous studies have demonstrated that human beings with Creutzfeldt-Jakob Disease have altered cerebrospinal fluid composition. 5, 6 Two-dimensional electrophoresis of the cerebrospinal fluid (CSF) demonstrated that these patients have dramatically increased concentra- tions of novel proteins. Noteworthy among these proteins was a single protein, which has been designated the 14-3-3 protein. The commercially available immunoassay for the 14-3-3 protein has been reported to be both sensitive (96%) and specific (88%) for the diagnosis of human Creutzfeldt-Jakob Disease. 6 Most nonspongiform human neurologic diseases appear to cause negative 14-3-3 results. 6 Although 2 prior studies have reported 14-3-3 results in sheep with scrapie, sensitivity and specificity of this procedure have not been critically evaluated. 7, 8, 15 The purpose of this study was to determine the sensitivity and specificity of the 14-3-3 immunoassay in the antemortem diagnosis of clinical scrapie using sheep of defined positive and negative scrapie status. This information is important because antemortem diagnostic tests will permit more accurate individual animal diagnosis and promote regulatory efforts to control and eradicate scrapie. Briefly, 50 l of CSF was mixed with 10 l of buffer containing 5% glycerol, 1% 2-mercaptoethanol, and 1% SDS and bromophenol blue. Sample proteins were separated by electrophoresis, transferred to nitrocellu-lose, and then stained by sequential incubation with an anti-14-3-3 gamma rabbit antibody and an alkalinephosphatase-conjugated antirabbit IgG antibody. Cerebrospinal fluid from a sheep with confirmed clinical scrapie was used as a positive control. This technique has been described elsewhere in greater detail. [5] [6] [7] Laboratory personnel responsible for performing the immunoassays (Igenex Laboratories, Palo Alto, CA) were blinded with regard to each sheep's scrapie status and the number of samples collected from scrapie-positive and -negative sheep. Assay results were reported using a subjective, semiquantitative scale as Ϫ, ϩ/Ϫ, 1ϩ, 2ϩ, or 3ϩ.
A McNemar's chi-squared test was performed to determine if the pattern of test results varied between positive and negative sheep using both 1ϩ and 2ϩ test endpoints. The pattern of test results was deemed to differ between the positive and negative sheep when P Ͻ 0.05. At the same test endpoints, sensitivity and specificity were calculated using standard epidemiologic methods. 14 Cerebrospinal fluid immunoassay results did not differ significantly between positive and negative sheep ( Table 1) . Using a 1ϩ test endpoint, sensitivity and specificity were 0.66 and 0.30, respectively. The use of a 2ϩ endpoint improved specificity (0.77); however, sensitivity was decreased (0.55).
Immunohistochemical (IHC) staining and microscopic examination of brain tissue currently is considered the standard for the detection of spongiform encephalopathy in sheep. This technique appears to be both highly sensitive and specific. When others examined the brains of 21 sheep with histopathologically confirmed scrapie after IHC staining, all 21 sheep were deemed positive. 11 Likewise, IHC examination of the brains of 14 normal sheep did not result in a single positive test result. Unfortunately, this technique requires harvesting and examination of brain tissue, and consequently, IHC examination is restricted to postmortem application.
The development of sensitive and specific antemortem diagnostic tests is critical to the development of control and eradication programs for SE in livestock. The 14-3-3 cerebrospinal fluid immunoassay has been proposed as an adjunct in the diagnosis of scrapie in sheep. In one report, 5 of 6 sheep with naturally acquired scrapie were test positive. 7 In a second report, 3 of 4 sheep with clinical scrapie were test positive. 15 Neither study examined the performance of the assay system in scrapie-negative sheep, rendering calculation of test specificity and test predictive values problematic.
The presented data suggests the 14-3-3 immunoassay has limited value in the diagnosis of clinical scrapie. Strongly positive test results were more common on positive than negative sheep, but the distribution of test outcomes overlapped greatly. Both test sensitivity and test specificity are less than optimal. It should be noted that cerebrospinal fluid samples were blotted onto nitrocellulose in the present study, and previous more favorable reports blotted samples onto polyvinylidene difluoride. 9 In the present study, regardless of the test endpoint used, both sensitivity and specificity were unacceptable for diagnostic use. The distributions of the 14-3-3 marker protein concentrations in control and clinically affected sheep have substantial overlap.
